This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

This report provides a snapshot of key aspects of behavioral health, serious mental illness, suicidal thoughts, and mental illness, substance use disorders, or both. The information is based on selected determinants of health, including race and ethnicity, income level, geography, and health insurance status.

This fact sheet (3 of 4) talks about what pregnant women with opioid use disorder should know about and expect after the birth of their baby. This resource includes information about neonatal abstinence syndrome, baby’s needs after birth, and do’s and don’ts for understanding and responding to baby’s needs.

This fact sheet (4 of 4) addresses the care of women with opioid use disorder (OUD) and care of their babies after pregnancy. This resource includes information on managing OUD, caring for baby, and do’s and don’ts for creating a healthy environment at home.

This manual offers best practices to states, tribes, and local communities on collaborative treatment approaches for pregnant women living with opioid use disorders, and the risks and benefits associated with medication-assisted treatment.

The National report presents indicators as measured through the 2017 National Survey on Drug Use and Health and the National Survey of Substance Abuse Treatment Services. State reports provide a snapshot of substance use and mental health in the United States.